COMMUNIQUÉS West-GlobeNewswire

Transactions under Novozymes’ stock buyback program
09/07/2018
Please read the full announcement in the attached PDF Attachment 2018_42_Stock_Buybackprogram_EN
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2018 After Market Close on July 16, 2018
09/07/2018
TUSTIN, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]
Allscripts to release second-quarter 2018 financial results August 2
09/07/2018
CHICAGO, July 09, 2018 (GLOBE NEWSWIRE) -- Allscripts Healthcare Solutions, Inc . (Nasdaq:MDRX) will report its financial results for the three months ended June 30, 2018, after the close of stock market hours on [...]
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114
09/07/2018
Triggers $4 million milestone payment under strategic collaboration with Nestlé Health Science REDWOOD CITY, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, [...]
Teneobio Announces Research Collaboration with Janssen to Develop Multispecific Antibodies for Oncology
09/07/2018
MENLO PARK, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company, announced today the initiation of a research collaboration and licensing agreement [...]
VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit
09/07/2018
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today [...]
The American Health Council Welcomes Daniel Lichtstein, MD to Board of Physicians
09/07/2018
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- The American Health Council welcomed Daniel Lichtstein, MD to its Board of Physicians for his outstanding contributions to the medical field. Currently serving as the Regional [...]
Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177
09/07/2018
Strategic Partnership Supports Commercialization Beyond Ongoing Phase 3 VISION Trial of 177Lu-PSMA-617 WEST LAFAYETTE, Ind. and GARCHING, Germany, July 09, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), and ITM [...]
Zafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study
09/07/2018
Information and data from study will advance understanding of medical history and medical events in people with PWS People living with PWS ages 5 and older and their caregivers are encouraged to participate BOSTON, July [...]
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma
09/07/2018
MADISON, Wis., July 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of [...]
Delcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands
09/07/2018
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that physicians at [...]
Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate
09/07/2018
LOS ALTOS, Calif. and LOS ANGELES, July 09, 2018 (GLOBE NEWSWIRE) -- Retrotope and collaborators led by Dr. Marie-Francoise Chesselet, the Charles H. Markham Professor of Neurology, and Interim Chair of the Department [...]
Nkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters
09/07/2018
SOUTH SAN FRANCISCO, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced two new additions to [...]
Biotricity Provides Fiscal 2018 First Quarter Updates for Shareholders
09/07/2018
With Bioflux FDA clearance and initial revenue, Biotricity focuses on sales growth and the development of its future products REDWOOD CITY, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a [...]
Eyenovia Appoints Michael Rowe as Vice President of Marketing Ahead of Initiation of Multiple Phase III Programs
09/07/2018
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to [...]
Nephros Announces Preliminary Financial Results for Second Quarter 2018
09/07/2018
Anticipates 57% Year-over-Year Revenue Growth; Establishes Specialty Renal Products Subsidiary SOUTH ORANGE, NJ, July 09, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company [...]
Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994
09/07/2018
Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending doses Data support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 clinical trial, planned to initiate around year- [...]
Assembly Biosciences Initiates Two Phase 2a Trials of ABI-H0731 for the Treatment of Hepatitis B Virus Infection
09/07/2018
Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO, July 09, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences [...]
Quark Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
09/07/2018
Quark reached agreement with FDA on the overall Phase 3 trial design with a new innovative primary endpoint FREMONT, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc., a late clinical-stage [...]

Pages